- Home
- OPP vs MDWD Comparison
OPP vs MDWD Comparison
Compare OPP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- MDWD
- Stock Information
- Founded
- OPP 2010
- MDWD 2000
- Country
- OPP United States
- MDWD Israel
- Employees
- OPP N/A
- MDWD N/A
- Industry
- OPP Finance/Investors Services
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- OPP Finance
- MDWD Health Care
- Exchange
- OPP Nasdaq
- MDWD Nasdaq
- Market Cap
- OPP 200.8M
- MDWD 172.6M
- IPO Year
- OPP N/A
- MDWD 2014
- Fundamental
- Price
- OPP $8.36
- MDWD $16.00
- Analyst Decision
- OPP
- MDWD Strong Buy
- Analyst Count
- OPP 0
- MDWD 1
- Target Price
- OPP N/A
- MDWD $28.00
- AVG Volume (30 Days)
- OPP 108.0K
- MDWD 42.5K
- Earning Date
- OPP 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- OPP 14.41%
- MDWD N/A
- EPS Growth
- OPP N/A
- MDWD N/A
- EPS
- OPP N/A
- MDWD N/A
- Revenue
- OPP N/A
- MDWD $20,141,000.00
- Revenue This Year
- OPP N/A
- MDWD $30.16
- Revenue Next Year
- OPP N/A
- MDWD $18.44
- P/E Ratio
- OPP N/A
- MDWD N/A
- Revenue Growth
- OPP N/A
- MDWD N/A
- 52 Week Low
- OPP $7.26
- MDWD $8.22
- 52 Week High
- OPP $8.83
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- OPP 23.91
- MDWD 36.64
- Support Level
- OPP $8.54
- MDWD $16.66
- Resistance Level
- OPP $8.79
- MDWD $17.63
- Average True Range (ATR)
- OPP 0.11
- MDWD 0.69
- MACD
- OPP -0.02
- MDWD -0.20
- Stochastic Oscillator
- OPP 2.22
- MDWD 9.02
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.